NANETS Lifetime Achievement Award

The North American Neuroendocrine Tumor Society Lifetime Achievement Award honors an individual who, over the course of their career, has provided outstanding contributions to neuroendocrine disease management through research, clinical practice or educational initiatives, as well as exceptional leadership in NANETS and dedication to its mission.

2017

odorisiom

M. Sue O'Dorisio, MD, PhD, University of Iowa

As a pediatric oncologist and Professor of Pediatrics, Dr. O'Dorisio enjoys caring for children with solid tumors, accepting the challenge of developing new therapies for these difficult to cure malignancies. She has basic research expertise in pharmacologic and molecular characterization of G protein-coupled receptors (GPCR); her laboratory research focuses on identification of GPCRs that can serve as theranostic targets for both imaging and therapy.

Children and young adults with neuroblastoma, medulloblastoma and neuroendocrine tumors have now become her clinical focus. She designed and conducted a Phase I protocol of 90Y-DOTATOC therapy targeting somatostatin receptors that drew subjects with these three tumor types from all over the US. She now has a Phase II, Theranostic trial utilizing 68Ga-DOTATOC as a diagnostic and 90Y-DOTATOC as a therapeutic agent in children and adults with somatostatin receptor positive malignancies.

In all of these endeavors, she seeks to mentor basic science and clinical trainees who will ultimately translate their ideas and hard work into improved length and quality of life for children and adults suffering from these malignancies. She has been an NIH funded principal investigator since 1976, PI of a T32 training grant in “Hematologic and Oncologic Diseases of Childhood” since 2004, and currently also serves as PI of a SPORE in Neuroendocrine Tumors. She has mentored over 30 graduate and medical students, 25 MD and PhD fellows, and 20 junior faculty members, including service on the mentoring teams for three T32 training programs.

odorisiot

Thomas O'Dorisio, MD, University of Iowa

Thomas O'Dorisio, MD is an endocrinologist at the University of Iowa Hospitals and Clinics. He is currently serving as the Director of the Neuroendocrine Tumor Program and Co-Leader Gastrointestinal Neuroendocrine MOG, Professor within the University of Iowa, in Iowa City, Iowa. He is affiliated with the University of Iowa, the University of Iowa Family Medicine Clinic, and the Iowa City VA Health Care System. He has over four decades of experience and specializes in carcinoid and neuroendocrine tumors that include familial neuroendocrine syndromes. He is board certified in Internal Medicine, and Endocrinology board eligible. 

In 1971, Dr. O'Dorisio received his MD from Creighton University, as well as an MS in Autonomy. He had an internship in internal medicine at Creighton University and completed his residency in internal medicine and fellowship in endocrinology at Ohio State University.

2014

oberg1

Kjell Öberg, MD, PhD, Uppsala University, Sweden

Kjell Öberg, MD, is Professor of Endocrine Oncology at the Medical Faculty of Uppsala University.

He is a specialist in endocrinology and internal medicine. He founded the Department of Endocrine Oncology at Uppsala University Hospital and has 30 years experience in the field of neuroendocrine tumors. He is the chairman of Centre of Excellence of Endocrine Tumors and Vice-chairman of the Department of Endocrine Oncology, University Hospital, Uppsala and Adjunct Professor of Surgery at Vanderbilt University.

Dr. Öberg has pioneered the treatment of carcinoid tumor patients with interferon and somatostatin analogs and developed assays for tumor markers such as Chromogranin A and radiological procedures including specialized PET scans. He is also one of the founders of the European Neuroendocrine Tumor Society.

In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia Type 1 (MEN1). Dr. Öberg has given many hundreds of presentations at international meetings and published more than 500 papers within his research field, H-factor 64 and more than 12,000 citations. Also, he is the author of numerous chapters on Carcinoid tumors in several international textbooks.

Dr. Öberg is a member of the Royal Society of Sciences, member of Swedish Society of Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Öberg is Chairman-Elect of ENETS and also a member of the NANETS Advisory Board as well as several other national and international research and scientific boards and many scientific journal review boards.

2012

Kvols

Larry Kvols, MD, Kvols Consulting

Larry Kvols, MD, is a consultant in neuroendocrinology at Kvols Consulting in Placitas, New Mexico.

He graduated from Baylor College of Medicine with his MD in 1970 and went on to do an internship, residency and fellowship at John Hopkins School of Medicine. From 1973-1975 Dr. Kvols completed a fellowship in hematology and oncology at Baltimore Cancer Research Center.

From 1975-1993 was a professor of oncology at Mayo Clinic before becoming the director of clinical research at Mallinckrodt. In 1996 Dr. Kvols became the director and CEO of cancer research and treatment at the University of New Mexico. Later in his career, he joined Moffitt Cancer Center as the director of neuroendocrine cancer research until he opened his own consulting company, Kvols consulting, in 2013.

According to his colleagues, Dr. Kvols personalizes his professional interest in patients with his excellent care and bedside manner.

2009

Warner

Richard Warner, MD, Mount Sinai

Richard Warner, MD, has dedicated his life's work to carcinoid research and treatment. He is Professor of Medicine (Gastroenterology) and serves as Medical Director of the Carcinoid Cancer Foundation, which is based in White Plains, New York, and is aided by other Mount Sinai faculty.

The nonprofit Carcinoid Cancer Foundation encourages and supports research and education on carcinoid and related neuroendocrine cancers. At Mount Sinai, where Dr. Warner recently became a full-time faculty member, he now helps train other doctors at the new Center for Carcinoid and Neuroendocrine Tumors.

“Carcinoid cancer is a little-known condition that only a small number of patients experience,” says Dr. Warner, who sees about 150 new cases every year. “Most doctors know very little about diagnosis and treatment of carcinoid tumors, but we have made significant inroads.”

These inroads include pioneering a new treatment that involves injecting microscopic radiation-bearing particles into the blood supply of the tumors. “In the coming year,” says Dr. Warner, “we will continue working with this treatment, with surgery, and we will also participate in clinical trials testing several very promising new drugs, as well as perfecting laboratory tests for diagnosis and monitoring. These are ongoing efforts that have prolonged and saved patients’ lives.”

Although rare, carcinoid tumors make up more than 40 percent of all small intestinal malignant tumors. They can occur anywhere in the gastrointestinal tract and pancreas and less commonly in the lungs and elsewhere. About 12,000 cases are diagnosed each year in the United States, and it has been estimated that there are 102,000 people in the country with this slowly progressing malignancy.

When these tumors metastasize, it can lead to carcinoid syndrome. Between 10 and 40 percent of such carcinoids secrete excessive levels of a range of hormones, most notably serotonin, causing flushing, diarrhea, wheezing, and heart failure. Dr. Warner first read about the syndrome more than 50 years ago.

Through websites, newsletters, conferences, and talks, Dr. Warner has contributed to the growing research, education, and support of understanding carcinoid cancer. Dr. Warner also helped form the North American Neuroendocrine Tumor Society, a society for doctors interested in this condition, and established many support groups across the country.

“Carcinoid cancer and carcinoid syndrome are orphan diseases that do not garner as much attention as more common diseases,” Dr. Warner says. “But we are working to change that.”